

# **Investigating the impact of physical activity on mitochondrial function in Parkinson's disease (PARKEX): Study protocol for a randomised controlled clinical trial**

Juan Carlos Magaña<sup>1,\*</sup>, Cláudia M. Deus<sup>2,3\*</sup>, Laura Baldellou<sup>4</sup>, Avellanet M<sup>5,6</sup>, Gea-Rodríguez E<sup>5,6</sup>, Silvia Enriquez Calzada<sup>7</sup>, Ariadna Laguna<sup>7,8,9</sup>, Marta Martínez-Vicente<sup>7</sup>, Jorge Hernández-Vara<sup>7</sup>, Maria Giné-Garriga<sup>1,4</sup>, Susana P. Pereira<sup>2,3,10,#,†</sup>, Joel Montané<sup>1,4,#,†</sup>

<sup>1</sup> Facultat de Psicologia, Ciències de l'Educació i de l'Esport Blanquerna, Ramon Llull University, Barcelona, Spain

<sup>2</sup> CNC-UC, Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal

<sup>3</sup> CIBB, Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal

<sup>4</sup> Facultat de Ciències de la Salut, Blanquerna, Ramon Llull University, Barcelona, Spain

<sup>5</sup> Hospital Nostra Senyora de Meritxell, Escaldes-Engordany, Andorra

<sup>6</sup> Universitat d'Andorra, Sant Julià de Lòria, Andorra.

<sup>7</sup> Grup de Malalties Neurodegeneratives de la Vall d'Hebron. Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain

<sup>8</sup> Aligning Science Across Parkinson's (ASAP) Collaborative Research Network; Chevy Chase, MD 20815, USA

<sup>9</sup> Institut de Neurociències-Autonomous University of Barcelona (INc-UAB); 08193 Cerdanyola del Vallès, Spain

<sup>10</sup> Laboratory of Metabolism and Exercise (LaMetEx), Research Centre in Physical Activity, Health and Leisure (CIAFEL), Laboratory for Integrative and Translational Research in Population Health (ITR), Faculty of Sports, University of Porto, Porto, Portugal

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

\* these authors contributed equally to this work

† these authors contributed equally to this work

# Correspondence should be addressed to:

Dr. Joel Montané

[joelmm@blanquerna.url.edu](mailto:joelmm@blanquerna.url.edu)

Blanquerna School of Health Science, Universitat Ramon Llull

Carrer de Padilla, 326-332, 08025 Barcelona, Spain

Dr. Susana P. Pereira

[pereirasusan@gmail.com](mailto:pereirasusan@gmail.com)

CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra,

Portugal

## Abstract

Parkinson's disease (PD) is characterized by the progressive dopaminergic neuron degeneration, resulting in striatal dopamine deficiency. Mitochondrial dysfunction and oxidative stress are associated with PD pathogenesis. Physical activity (PA) has been shown to ameliorate neurological impairments and to impede age-related neuronal loss. In addition, skin fibroblasts have been identified as surrogate indicators of pathogenic processes correlating with clinical measures. The PARKEX study aims to compare the effects of two different PA programs, analyzing the impact on mitochondrial function in patients' skin fibroblasts as biomarkers for disease status and metabolic improvement. Early-stage PD patients (n=24, H&Y stage I to III) will be randomized into three age- and sex-matched groups. Group 1 (n=8) will undergo basic physical training (BPT) emphasizing strength and resistance. Group 2 (n=8) will undergo BPT combined with functional exercises (BPTFE), targeting the sensorimotor pathways that are most affected in PD (proprioception-balance-coordination) together with cognitive and motor training (Dual task training). Group 3 (n=8) will serve as control (sedentary group; Sed). Participants will perform three sessions per week for 12 weeks. Assessment of motor function, quality of life, sleep quality, cognitive aspects and humor will be conducted pre- and post-intervention. Patient skin fibroblasts will be collected before and after the intervention and characterized in terms of metabolic remodeling and mitochondrial bioenergetics. Ethical approval has been given to commence this study. This trial is registered at [clinicaltrials.gov](https://clinicaltrials.gov) (NCT05963425)

**Keywords:** Physical activity; Exercise therapy; Biomarker; Neuroprotection; Mitochondrial diseases; Parkinson's disease

## Introduction

Parkinson's disease (PD) is a disorder characterized by the progressive degeneration of dopaminergic neurons resulting in a deficiency of dopamine in the *striatum* in the basal ganglia [1]. PD patients experience both motor and non-motor symptoms, including anxiety, depression, sleep and gastrointestinal alterations, among others. The motor symptoms typically manifest gradually, initially asymmetrical and later bilateral. The most common primary motor symptoms include *akinesia* (lack of spontaneous voluntary movement), *bradykinesia* (slowness of movement), resting tremor (hands, arms, legs, jaw, and face), rigidity (arms, legs, and trunk), and postural instability. Additionally, people with PD may experience difficulties with balance and coordination [2]. Although the exact mechanism behind the neurodegeneration of dopaminergic cells remains uncertain, current understanding suggests an interaction between genetic and environmental factors as contributors [3,4].

Physical activity (PA) has a very important role and exerts a significant impact in patients with PD. Numerous evidence point to the remodelling and neuroplastic power of PA, including the role of muscle secretory activity in neurodegenerative diseases [5]. Further, PA may be responsible for both systemic [5,6] and neural [7,8] plasticity, defining the concept of *neural systemic dual plasticity* (NSDP) [9]. In the design of this protocol, we aim to determine the effect of exercise at the cellular and molecular level and having as its epicentre mitochondrial function related to changes in gene expression and functionality of mitochondria [10,11]. During PA, a number of myokines and metabolites are released into the bloodstream, many of which can cross the blood-brain barrier (BBB) and exert effects on the central nervous system, in this case the effects of exercise at the systemic level begin as secondary plasticity, that follow different signalling pathways and by passing the BBB has the potential to become primary plasticity [9].

Research has demonstrated that PA not only prevents cognitive decline and the risk of dementia in older adults [12] and other neurodegenerative diseases [13,14] but also mitigates motor deficits, increases new neuron formation, ameliorates neurological impairments, and helps counteract age-related neuronal loss [15]. Further, recent studies have indicated that intensive and cognitively demanding programs are capable of inducing plastic brain changes in individuals with PD [16]. PA plays a crucial role in modulating cortical activity among patients with PD [17]. It has been described that the

activation of cortical areas during PA can be attributed to the increased intracerebral blood flow induced by exercise. A study evaluated the motor symptoms of PD using the Unified Parkinson's Disease Rating Scale-III (UPDRS-III) and compared three groups of patients. Two groups participated in different PA programs, while the third group underwent physiotherapy. Remarkably, both PA groups exhibited a significant improvement of 27.5% in motor symptoms as assessed by UPDRS-III pre and post intervention, whereas the physiotherapy group showed a modest improvement of 2.9%. Notably, all the three groups demonstrated enhanced functional capacity at the end of the intervention [18]. These findings underscore the substantial benefits of PA in ameliorating motor symptoms and enhancing functional outcomes in individuals with PD. On the other hand, the relationship of PA with specific neurological benefits [19], highlights that PA activates a series of processes responsible for maintaining and protecting nerve cells, a phenomenon often referred to as physiological neuroprotection systems. PA favors the production of compensation mechanisms through a reorganization of damaged neural circuits [20].

In healthy subjects, the beneficial effects induced by PA are mediated by improved mitochondrial function and mitophagy [21]. This is relevant, since mitochondrial dysfunction is a key phenomenon associated with early PD, which occurs before the onset of motor symptoms [22]. PA has been shown to improve mitochondrial respiration, thereby affecting adenosine triphosphate (ATP) production and overall mitochondrial function. Indeed, both acute exercise and resistance exercise increase breathing and respiratory control index [23,24].

Moreover, skin fibroblasts from patients with PD have emerged as a valuable resource for studying this neurodegenerative disorder and identifying potential biomarkers [25]. Since acquiring human brain samples is only feasible *postmortem*, several researchers have turned to the easily accessible peripheral samples, such as skin fibroblasts. These studies emphasize that fibroblasts, originating from the same genetic lineage as neurons [26], can serve as reliable indicators of cumulative cellular damage related to the age and patient-specific habits [27]. The relevance of skin fibroblasts as a surrogate model in this research lies in their ability to mirror specific cellular deficiencies commonly observed in nigral neurons. These deficits serve as indicators the neurodegenerative process of PD and can be detected in fibroblasts from PD patients [27]. Hence the importance of

fibroblasts as a surrogate model for physiopathological processes, as it would allow mitochondrial function to be correlated with clinical measures, such as motor function by means of the MDS-UPDRS III scale [28]. Our recent studies examining skin fibroblasts from PD patients have revealed metabolic and mitochondrial abnormalities [23], establishing a clear link between mitochondrial dysfunction in skin fibroblasts samples from PD patients and PD pathogenesis. These investigations demonstrated decreased oxygen consumption rate (OCR), proton leak, maximal respiration, respiratory replacement capacity, and OCR-linked ATP levels in skin fibroblasts from patients with PD, providing clear evidence of compromised mitochondrial function.

The aim of this clinical study is to explore the impact of PA on metabolic remodeling, utilizing a less invasive model to investigate PD and its pathogenic mechanisms. Specifically, the study aims to examine fibroblasts derived from PD patients, which serve as an accessible and informative model to gain insights into the underlying deficits affecting neurons. By investigating the beneficial mechanisms associated with PA and studying the pathophysiological alterations within fibroblasts, this research holds the potential to deepen our understanding of PD and facilitate the development of novel diagnostic tools, and revolutionary therapeutic interventions applicable to clinical practice.

## **Methods and analysis**

### **Study design**

PARKEX trial is a randomized clinical trial with an open design (registered at [clinicaltrials.gov](https://clinicaltrials.gov); NCT05963425). It is a non-pharmacologically interventional study, with a total of twenty-four patients. Screening and assessment visits are occurring in both neurology and PA laboratory settings.

A SPIRIT schedule and overview of the study design can be found in Figure 1 and Figure 2 below.

	2023												2024												2025											
Month	M1	M2	M3	M4	M5	M6	M7	M8	M9	M10	M11	M12	M1	M2	M3	M4	M5	M6	M7	M8	M9	M10	M11	M12	M1	M2	M3	M4	M5	M6	M7	M8	M9	M10	M11	M12
Submission to ethics committee	█																																			
Study registration at clinicaltrials.gov	█						█																													
Patient recruitment																																				
Initial visit at VHIR and informed consent																																				
Randomization																																				
Questionnaires and Fibroblast extraction																																				
Intervention - Exercise Programs																																				
Fibroblast metabolic characterisation																																				
Data analysis																																				
Study dissemination																																				

Figure 1. SPIRIT schedule for the PARKEX study




Figure 2. Comprehensive overview of the PARKEX study design.

This protocol has been developed following the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist [29].

### **Subject Recruitment**

Participants for the study will be recruited by the Grup de Malalties Neurodegeneratives of the Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. To ensure the minimum required sample size of 24 patients, as stipulated in the project, the VHIR researchers will leverage their connections with the Catalan Parkinson's Association and other Movement Disorders Units in prominent hospitals across the state. Participants who meet the inclusion criteria and sign the informed consent will be recruited and randomized.

### **Sample Size Calculation**

The sample size for this study was determined using the GRANMO program with the model of observed proportions with respect to a reference. For the calculation it has been taken into account that the "maximal respiration" is the key indicator to determine the effects of PA on mitochondrial function, because the entire respiratory chain is forced to the maximum. The calculation has been made accepting an  $\alpha$  risk of 0.05 and a beta risk of less than 0.2 in a two-sided contrast. Based on preliminary data, there is a difference of "maximal respiration" equal to or greater than 0.263 units [23]. It is assumed that the proportion in the reference group is 0.019 in people older than 50 years [30]. Being an interventional study, the percentage of necessary replacements has been predicted to be 20%.

### **Eligibility criteria**

To be included in this study, subjects must meet specific criteria. These criteria include having a medical diagnosis of idiopathic PD, falling within stages of I-III on the H&Y scale in the 'on' phase, and demonstrating a good cognitive status with a score 26 or higher on the Montreal Cognitive Assessment (MoCA). Participants must be between 50 and 70 years old and capable of walking independently for at least six minutes. In addition, it is important that the subjects have not made any changes to their medication



regimen in the last month. The International Physical Activity Questionnaires (IPAQ) will be used to normalize the groups based on the basal levels of PA [31]. Once the subjects are selected, they will receive a detailed explanation of the research procedures, and the subjects will voluntarily express their consent to participate in this study, signing the informed consent.

Certain criteria will lead to the exclusion of subjects from participation in this study. These criteria encompass the presence of any pathology other than idiopathic PD, cognitive impairment with a MoCA score below 26 points, uncontrolled cardiovascular disease, diabetes, visual impairment, or recent musculoskeletal disorders in the upper or lower extremities that may interfere with balance and locomotion. Additionally, individuals currently undergoing another therapeutic exercise protocol or who have undergone surgery aimed at influencing a specific PD symptom will not be eligible to participate.

### **Randomization**

All patients who provide their consent to participate in the study and fulfil the inclusion criteria will be randomized. A sample block randomization method will be employed, dividing the participants in three groups: two intervention groups and one control group. The allocation of individuals to intervention or control groups will be blind to assessors and participants. An independent investigator, uninvolved in the study, will perform the random assignment of subjects into the three groups. This will be done using a computer-generated random allocation table, stratified based on the PD stages (i.e., according to H&Y classification stages I, II, III), basal physical activity levels, sex, and age.

### **Intervention**

Two different programs are designed in order to investigate the effect of PA on mitochondrial function in skin fibroblasts of patients with PD.

The first group (n=8) will undergo basic physical training (BPT) focused on strength and resistance. The second group will engage in BPT combined with functional exercises (BPTFE), which includes cognitive and dual task training. A third group, the sedentary group, will serve as the control. The intervention in the two PA programs will last 3 months.

The interventions will be conducted in group settings, with 8 patients per group, and each session will last for 60 minutes. The frequency of the sessions will be 3 times a week. The intervention programs will be structured into 3 meso-cycles of 4 weeks. During the initial two weeks, the workloads will be maintained to facilitate the adaptation period. For the BPTFE program, in addition to adapting to the load, participants will also need to adapt to complex motor execution tasks. Starting from the third week, the workload will progressively increase.

In both PA programs, exercises will target the large muscle groups, with a component/emphasis on the eccentric phase of concentration. The *kBox4* Platform, a device designed to maximize performance and training outcomes, will be used to enhance the eccentric phase of the exercises. This device, provided by Exxentric AB (Stockholm, Sweden), a company specialized in innovative and evidence-based training equipment and methods, will be loaned for the study. *kBox4* is controlled by a specific program, *Kmeter*, which records and stores all the information (duration, intensity, repetitions, etc.) of each movement. Exxentric *kBox4* will be adapted with special harnesses, insurances on the wall and in front of support bars, according to the needs of the patients. In addition to the major muscle groups, specific attention will be given to the key muscles involved in the gait cycle, such as the tibialis anterior, medial gastrocnemius, rectus femoris, and hamstrings, from a biomechanical perspective. This aspect will be common to both programs, with the only difference being that the BPT program will have a greater workload due to the division of activity time between functional exercises and Dual Task Training in the BPTFE program.

## **Experimental groups**

### ***Intervention group 1 - Basic Physical Training (BPT)***

This PA program will be based only on the work of BPT, in which specifically and mainly the Strength (S) and Resistance (R) will be worked, but also flexibility.

### ***Intervention group 2 - Basic Physical Training with Functional Exercises (BPTFE)***

In addition to the BPT program (which includes the transverse focus on strength and resistance exercises), this intervention group will incorporate functional exercises that involve dual task training. The dual task training can encompass both motor-motor and motor-cognitive activities. This means that coordinated exercises will be performed, with cognitive activities introduced at the extremes of the movement. This approach ensures engagement of both physical and cognitive abilities during the PA sessions.

### ***Control group - Sedentary (Sed)***

Participants in the control group will maintain their regular daily routines throughout the study period. Weekly interviews will be conducted by the researchers to ensure that their routines remain unchanged and to minimize any effect due to the interaction with the researchers. After the final evaluation, at the end of the study (6 months), this group will receive 3 months of PA based on the program that has obtained the most favorable outcomes, in terms of symptoms management and quality of life.

## **Outcome assessment and measurement procedures**

The primary outcome of the PARKEX study is the mitochondrial (dys)function, while secondary outcomes include motor function, quality of life, sleep, cognitive aspects and mood. Additionally, the study aims to perform the metabolic characterization of cutaneous fibroblasts from PD patients, evaluating the effects of PA-induced metabolic remodeling on oxidative stress, mitochondrial quality control,

mitochondrial DNA copy number, mitochondrial protein expression and transcript levels in skin fibroblasts of PD patients.

To gather pre-intervention and post-intervention clinical parameters, the following experimental design procedures will be followed in 2 different phases (see Table 1, Table 2 and Figure 3):

Table 1: Phase 1 in Spain: Secondary outcome measures and their assessment instruments.

<b>Secondary outcome measures</b>	<b>Instruments to assess the study variable</b>
<b>Functional Assessment - Balance</b>	TINETTI scale and BERG Balance Scale
<b>Functional Assessment</b>	Six-minute walk test (6MWT)
	1-minute sit-to-stand test (STS). Times you get up and sit down, in a chair
	Timed Up and Go (TUG). Time to get up from a chair, walk 3 m, turn around, walk backwards and sit down
<b>Motor function</b>	Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS I-III)
<b>Cognitive aspects</b>	Montreal Cognitive Assessment (MoCA)
<b>Quality of life</b>	Parkinson's Disease Questionnaire (PDQ-39)
<b>Humour (Profile of Mood States)</b>	BDI-2 Beck's Depression Inventory
<b>Sleep quality</b>	Parkinson's Disease Sleep Scale-2 (PDSS-2)
<b>Non-motor symptoms</b>	MDS-NMS scale, Scopa-Aut

Table 2: Phase 2 in Portugal: Assessment of surrogate patterns for mitochondrial (dys)function in patients' fibroblasts using molecular biology techniques

Primary outcome measures	Specific objectives	Description	Mitochondrial function analysis
Evaluate the effect of PA on mitochondrial remodeling in skin fibroblasts from patients with PD, namely in the mitochondrial maximal respiration	Assess the effects of metabolic remodeling on mitochondrial oxygen consumption rate, oxidative stress, mitochondrial quality control, mitochondrial DNA copy number, mitochondrial proteins and transcripts	Characterize the effects of PA remodeling on fibroblast from patients with PD, in terms of mitochondrial biogenesis, oxidative stress, and mitochondrial quality control	<ul style="list-style-type: none"> <li>- Determination of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) using a Seahorse XFe96 Extracellular Flux Analyzer (Agilent Technologies, Germany).</li> <li>- qRT-PCR (using SsoFast Eva Green Supermix, in a CFX96 real time-PCR system (Bio-Rad, Hercules, CA, USA)) for transcripts of interest related to mitochondrial biogenesis, dynamics, epigenetic regulation, oxidative phosphorylation, oxidative stress (SOD1, SOD2, NFE2L2), quality control mechanisms, including autophagy and ubiquitin-proteasome system (UPS).</li> <li>- Regulation and abundance of mitochondrial proteins by immunoblotting</li> <li>- Enzymatic activities (ex, mitochondrial complex I and citrate synthase)</li> </ul>

## PARKEX trial

### Experimental Design

- **Sample size calculation**  
(GRANMO program)
- **Subject recruitment**  
(VHIR)
- **Eligibility criteria**  
50-70 years old  
Idiopathic PD medical diagnostic  
Hoehn and Yahr scale at stage of I-III  
MoCA=> 26
- **Randomization**  
(Computer-generated random allocation table)
- **Clinical parameters and fibroblasts collection**
- **Exercise intervention (12 weeks)**
- **Clinical parameters and fibroblasts collection**




Figure 3. Graphical representation of PARKEX study design, highlighting the interventions and respective experimental groups, timing of sample collection, and analyzed endpoints

## Baseline assessment

Each participant will need to sign an informed consent prior to being interviewed. The interview will include a comprehensive medical history review and a complete anamnesis including the collection of medication control, gathering data on their current health status and also the chronology of their specific pathology. The clinical history and neurological examination will be prepared to confirm inclusion-exclusion criteria, assessing motor strength, muscular tone and pathological reflexes. Familiarization sessions will also be conducted before the intervention. In this session, the participants will be provided with a smart band (Amazfit Band®) in order to normalize the basal levels of PA that the patients may have throughout the study.

Both intervention and control groups will undergo a baseline evaluation, including functional assessment, PA tests, motor assessment, medication control, health assessment and skin biopsy (small tissue samples) for fibroblast extraction from the skin of the neck.

### 1. Baseline evaluation

A battery of tests will be performed (Figure 2), encompassing a complete neurological examination to confirm inclusion-exclusion criteria using the MDS-UPDRS questionnaire; psychological tests aimed at assessing cognitive aspects include the MoCA questionnaire; quality of life (using the PDQ39 questionnaire), mood (using the BDI-2 questionnaire), balance (TINETTI), sleep (PDSS test), and dysautonomia (SCOPA-AUT test). The 6-minute walk test (6MWT) to evaluate the functional capacity and endurance of participants will be conducted according to standardized guidelines. These tests and questionnaires will be evaluated pre- and post-intervention (at 3 months) and 3 months after the end of the intervention (6 months after the initial evaluation).

The complexity and extent of motor and non-motor symptoms of PD inevitably lead to a complex pathway of multidrug medication use, generally referring to the use of 5 or more medications at the same time [32,33]. In the same line, a meta-analysis showed that there is a high risk of polypharmacy and hyperpolypharmacy in older patients with PD [34]. Furthermore, extended use of levodopa may result in motor fluctuations and involuntary movements known as levodopa-induced dyskinesia (LID) [35]. Nevertheless, exercise can enhance the effectiveness of levodopa, leading to improved motor response, while also preventing biochemical changes (primary plasticity) in specific basal ganglia regions

implicated in the development of LID [36]. To this end, we will obtain the complete medication history from each participant, including details of all prescribed medications, over-the-counter drugs, and supplements. Name, dosage, frequency, and duration of each medication will be documented. Prior to the intervention, participants would be instructed to continue their regular medication regimen without making any changes unless advised by their healthcare provider. Throughout the study, participants would be regularly reminded to report any changes or adjustments.

## 2. Health assessment

A comprehensive health assessment will be conducted by the Neurodegenerative Diseases Research Group at VHIR to compile a complete medical history. Health parameters (heart rate, blood pressure, anthropometric measurements, height, weight, BMI) will be determined before and after intervention.

## 3. Skin fibroblast extraction

Specialized neurologists from the Neurodegenerative Diseases Research Group at VHIR will perform the biopsy for skin fibroblast isolation. This will allow us to investigate patients' fibroblast's mitochondrial function, which was being described as impacted in neurodegenerative diseases such as PD, and thus enabling the opportunity to verify the effect of applying a PA program in these patients.

Skin fibroblast biopsies will be collected before and after the intervention in all three groups. The collected cells will then be cultured, expanded, and frozen at VHIR. Subsequently, the cells will be sent to the Center for Neuroscience and Cell Biology at the University of Coimbra, Portugal for further functional and molecular analysis.

### **Mitochondrial analysis**

The analysis of mitochondrial function and metabolism in skin fibroblasts from patients will encompass various parameters. Metabolic fluxes of the cells will be assessed using the Seahorse XF<sup>e</sup>96 Extracellular Flux Analyzer [23]. Additionally, mitochondrial membrane potential and morphology will be evaluated using TMRM staining, while cellular oxidative stress will be measured using hydroethidine (HET) and CM-H2DCFDA. Moreover, ATP levels will be determined using a high-



throughput luminescent method [37]. The expression of relevant transcripts associated with mitochondrial biogenesis, stress responses, oxidative phosphorylation, and auto(mito)phagy will also be evaluated [23]. This includes enzymes such as superoxide dismutase, catalase [38], glutathione reductase, parkin and PINK1 proteins, the mitochondrial transcription factor A (TFAM), the regulator of mitochondrial biogenesis (such as PGC1- $\alpha$ ), and metabolism (such as AMPK- $\alpha$ ) [37]. The evaluation of these parameters aims to unravel the molecular mechanism through which PA promotes mitochondrial metabolism remodeling in PD patients. Furthermore, this analysis seeks to identify new intervention targets for PD and demonstrate, for the first time, that the metabolic and mitochondrial beneficial effects of PA in PD patients can be detected through observable biochemical changes in their skin fibroblasts. By uncovering these biochemically-detectable alterations, we can gain valuable insights into the specific mechanisms underlying the metabolic and mitochondrial improvements resulting from PA, providing a foundation for targeted interventions in PD.

### **Statistical analysis**

Data analysis will be performed using SPSS v.20 (IBM SPSS Statistics). Regarding descriptive analysis, all the variables of the sample will be analyzed by means of relative and absolute frequencies, as well as measures of dispersion and central tendency frequencies. Repeated measures analysis will be performed using the appropriate mixed effects model, accounting for homogeneous or inhomogeneous samples. This analysis will determine the possible changes between the different moments of the intervention and to evaluate which types of intervention yield the greatest physical benefits, whether in terms of mitochondrial function, physiological factors, quality of life, or cognitive and emotional aspects. Spearman's rho and Pearson's r will be used to evaluate the association between two variables that have ordinal categories. The normality of the distribution of the results for each group's results will be assessed using the Shapiro-Wilk normality test, with a significant threshold set at  $\alpha=0.05$ . If the data follow a normal distribution, a parametric paired t-test will be conducted. Otherwise, the Mann-Whitney test will be used. Statistical significant differences will be considered for statistical test values with  $p<0.05$ .

## **Ethics**

The research project has received approval from the Research Ethics Committee of the Faculty of Psychology and Education and Sports Sciences (Blanquerna, Universitat Ramon Llull) on 27/01/23 (2021008D), as well as from the Ethics Committee for Research with Medicines at Vall d'Hebron University Hospital (PR(AG)574/2021). Participants will sign informed consent prior to the participation of the trial.

## **Discussion**

Accumulating evidence supports the potential benefits of PA for patients with PD, including both general health improvements and disease-specific effects. However, the exact mechanism connecting skeletal muscle-increased activity and mitochondrial remodeling in PD are poorly elucidated. The PARKEX study is the first clinical trial that aims to evaluate the effects of two PA programs on skin fibroblasts mitochondrial function from patients with PD, as well as their impact on motor function, quality of life, sleep, cognitive and mood aspects. The 12-week implementation of the BPT and BPTFE programs is expected to positively impact relevant clinical aspects of PD by enhancing systemic mitochondrial function, restoring mitochondrial metabolism, and influencing gene expression patterns. These improvements are anticipated to translate into potential neuroprotective effects. Additionally, the PARKEX clinical trial will provide insights into the degree of mitochondrial function improvements in PD through a comparative analysis of BPT and BPTFE programs and aims to unveil, for the first time, the biochemically-detectable changes in skin fibroblasts from PD patients that reflect the metabolic and mitochondrial benefits of PA. This crucial observation will demonstrate the tangible and measurable effects of PA on mitochondrial function at the cellular level. Understanding the regulation of the mitochondrial function by PA in PD holds significant promise in defining interventions to delay disease onset and developing new therapeutic approaches not only for PD but also for other neurodegenerative disorders.

## **Trial status**

As of the time of this publication, the study is actively underway in accordance with protocol version 1.3, dated May 17, 2023. Recruitment of participants started in September 15<sup>th</sup> and is anticipated to be completed by October 2023. The intervention phase and the last follow-up assessments are expected to be concluded by January 2024. The study is progressing according to the planned timeline, and data collection and analysis will commence thereafter to generate meaningful results.

## **Competing Interest**

The authors have declared that no competing interests exist.

## **Supporting information**

S1 Checklist. SPIRIT 2013 checklist: Recommended items to address in a clinical trial protocol and related documents

S2 Clinical trial protocol, v4, V4; December 05 2022

## **Acknowledgments**

The authors would like to thank all PD patients who will contribute to the performance of the study and the Associació Catalana per al Parkinson for their invaluable help in diffusion of the study and the subject recruitment.

## **Funding**

This work was supported by research funds provided by the Ajuts a l'Activitat de Recerca del Personal Docent i Investigador de la Universitat Ramon Llull (2021-URL-Proj-004), the Funding program PGRiD 2019–2021 of the Faculty of Psychology, Education, and Sport Sciences (APR-FPCEE2122/04) and by the

European Regional Development Fund (ERDF), through the Centro 2020 Regional Operational Programme under project CENTRO-01-0246-FEDER-000010 (Multidisciplinary Institute of Ageing in Coimbra) through the COMPETE 2020 - Operational Programme for Competitiveness and Internationalisation and Portuguese national funds via FCT - Fundação para a Ciência e a Tecnologia, under projects 2022.01232.PTDC, UIDP/04539/2020 and LA/P/0058/2020. S.P.P. was supported by FCT Pos-Doctoral fellowship SFRH/BPD/116061/2016. The authors would also like to acknowledge the support of the Faculty of Psychology, Education, and Sport Sciences, Blanquerna in providing funding for Predoctoral Researchers in Training (PFU) for J.C.M.

### Author contributions

J.C.M., C.M.D., L.B., and J.M. wrote the original draft preparation of the manuscript. M.A., E.G.R., S.E.C., A.L., J.H.V., M.M.V., M.G.-G., J.M. and S.P.P. wrote, reviewed and edited the manuscript. All authors critically revised the final form of the manuscript. All authors have read and agreed to the published version of the manuscript.

### References

- 1 Drozak J, Bryła J. [Dopamine: not just a neurotransmitter]. *Postepy Hig Med Dosw (Online)*. 2005;59:405–20.
- 2 Moustafa AA, Chakravarthy S, Phillips JR, *et al*. Motor symptoms in Parkinson's disease: A unified framework. *Neurosci Biobehav Rev*. 2016;68:727–40.
- 3 Gao H-M, Hong J-S. Gene-environment interactions: key to unraveling the mystery of Parkinson's disease. *Prog Neurobiol*. 2011;94:1–19.
- 4 Logroscino G. The role of early life environmental risk factors in Parkinson disease: what is the evidence? *Environ Health Perspect*. 2005;113:1234–8.
- 5 Lee B, Shin M, Park Y, *et al*. Physical Exercise-Induced Myokines in Neurodegenerative Diseases. *IJMS*. 2021;22:5795.
- 6 Leuchtmann AB, Adak V, Dilbaz S, *et al*. The Role of the Skeletal Muscle Secretome in Mediating Endurance and Resistance Training Adaptations. *Front Physiol*. 2021;12:709807.
- 7 Swain RA, Berggren KL, Kerr AL, *et al*. On aerobic exercise and behavioral and neural plasticity. *Brain Sci*. 2012;2:709–44.
- 8 Marino G, Campanelli F, Natale G, *et al*. Intensive exercise ameliorates motor and cognitive symptoms in experimental Parkinson's disease restoring striatal synaptic plasticity. *Sci Adv*. 2023;9:eadh1403.

- 9 Magaña JC, Deus CM, Giné-Garriga M, *et al.* Exercise-Boosted Mitochondrial Remodeling in Parkinson's Disease. *Biomedicines*. 2022;10:3228.
- 10 Hawley JA, Hargreaves M, Joyner MJ, *et al.* Integrative biology of exercise. *Cell*. 2014;159:738–49.
- 11 Bassel-Duby R, Olson EN. Signaling pathways in skeletal muscle remodeling. *Annu Rev Biochem*. 2006;75:19–37.
- 12 Paillard T. Preventive effects of regular physical exercise against cognitive decline and the risk of dementia with age advancement. *Sports Med Open*. 2015;1:20.
- 13 Xu M, Zhu J, Liu X-D, *et al.* Roles of physical exercise in neurodegeneration: reversal of epigenetic clock. *Transl Neurodegener*. 2021;10:30.
- 14 Valenzuela PL, Castillo-García A, Morales JS, *et al.* Exercise benefits on Alzheimer's disease: State-of-the-science. *Ageing Research Reviews*. 2020;62:101108.
- 15 Gligoroska JP, Manchevska S. The effect of physical activity on cognition - physiological mechanisms. *Mater Sociomed*. 2012;24:198–202.
- 16 Blesa J, Trigo-Damas I, Quiroga-Varela A, *et al.* Oxidative stress and Parkinson's disease. *Front Neuroanat*. 2015;9:91.
- 17 Franzén E, Johansson H, Freidle M, *et al.* The EXPANd trial: effects of exercise and exploring neuroplastic changes in people with Parkinson's disease: a study protocol for a double-blinded randomized controlled trial. *BMC Neurol*. 2019;19:280.
- 18 Carvalho A, Barbirato D, Araujo N, *et al.* Comparison of strength training, aerobic training, and additional physical therapy as supplementary treatments for Parkinson's disease: pilot study. *Clin Interv Aging*. 2015;10:183–91.
- 19 Barrios Herrero L, López Ferradaz MA. Aportes del ejercicio físico a la actividad cerebral. 2011;16:1–7.
- 20 Vera Hinojosa JA, Lissette Flores K, del Carmen Alvarado C, *et al.* La actividad física como factor benéfico a nivel neurológico. 2019;3:1403–20.
- 21 Drake JC, Laker RC, Wilson RJ, *et al.* Exercise-induced mitophagy in skeletal muscle occurs in the absence of stabilization of Pink1 on mitochondria. *Cell Cycle*. 2019;18:1–6.
- 22 Morales-Martínez A, Martínez-Gómez PA, Martínez-Fong D, *et al.* Oxidative Stress and Mitochondrial Complex I Dysfunction Correlate with Neurodegeneration in an  $\alpha$ -Synucleinopathy Animal Model. *Int J Mol Sci*. 2022;23:11394.
- 23 Deus CM, Pereira SP, Cunha-Oliveira T, *et al.* Mitochondrial remodeling in human skin fibroblasts from sporadic male Parkinson's disease patients uncovers metabolic and mitochondrial bioenergetic defects. *Biochim Biophys Acta Mol Basis Dis*. 2020;1866:165615.
- 24 Yoo S-Z, No M-H, Heo J-W, *et al.* Effects of Acute Exercise on Mitochondrial Function, Dynamics, and Mitophagy in Rat Cardiac and Skeletal Muscles. *Int Neurol J*. 2019;23:S22-31.
- 25 Ambrosi G, Ghezzi C, Sepe S, *et al.* Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson's disease. *Biochim Biophys Acta*. 2014;1842:1385–94.
- 26 Auburger G, Klinkenberg M, Drost J, *et al.* Primary skin fibroblasts as a model of Parkinson's disease. *Mol Neurobiol*. 2012;46:20–7.
- 27 Milanese C, Payán-Gómez C, Galvani M, *et al.* Peripheral mitochondrial function correlates with clinical severity in idiopathic Parkinson's disease. *Mov Disord*. 2019;34:1192–202.
- 28 Goetz CG, Tilley BC, Shaftman SR, *et al.* Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results: MDS-UPDRS: Clinimetric

Assessment. *Mov Disord*. 2008;23:2129–70.

29 Chan A-W, Tetzlaff JM, Altman DG, *et al*. SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med*. 2013;158:200–7.

30 Garcés M, Crespo Puras M del C, Finkel Morgenstern L, *et al*. Estudio sobre las enfermedades neurodegenerativas en España y su impacto económico y social. 2016. <https://hdl.handle.net/20.500.14352/27610>

31 Gilby J, Carroll C, Marsden J. Measures of physical activity in Parkinson’s disease (MAPD). *Physiotherapy*. 2022;114:e99.

32 McLean G, Hindle JV, Guthrie B, *et al*. Co-morbidity and polypharmacy in Parkinson’s disease: insights from a large Scottish primary care database. *BMC Neurol*. 2017;17:126.

33 Masnoon N, Shakib S, Kalisch-Ellett L, *et al*. What is polypharmacy? A systematic review of definitions. *BMC Geriatr*. 2017;17:230.

34 Bhagavathula AS, Tesfaye W, Vidyasagar K, *et al*. Polypharmacy and Hyperpolypharmacy in Older Individuals with Parkinson’s Disease: A Systematic Review and Meta-Analysis. *Gerontology*. 2022;68:1081–90.

35 Pandey S, Srivanitchapoom P. Levodopa-induced Dyskinesia: Clinical Features, Pathophysiology, and Medical Management. *Ann Indian Acad Neurol*. 2017;20:190–8.

36 Muhlack S, Welnic J, Woitalla D, *et al*. Exercise improves efficacy of levodopa in patients with Parkinson’s disease. *Mov Disord*. 2007;22:427–30.

37 Deus CM, Pereira SP, Cunha-Oliveira T, *et al*. A mitochondria-targeted caffeic acid derivative reverts cellular and mitochondrial defects in human skin fibroblasts from male sporadic Parkinson’s disease patients. *Redox Biol*. 2021;45:102037.

38 Grilo LF, Martins JD, Cavallaro CH, *et al*. Development of a 96-well based assay for kinetic determination of catalase enzymatic-activity in biological samples. *Toxicol In Vitro*. 2020;69:104996.